Atomwise and Sanofi have entered a strategic and exclusive research partnership to use the former’s artificial intelligence (AI)-driven AtomNet platform to discover and research up to five drug targets computationally.
The approach of Atomwise makes the process of drug discovery more logical and efficient by moving away from serendipitous discovery and toward a search that is structure-based.
By incorporating deep learning for structure-based drug design, the AtomNet platform facilitates the quick, AI-driven search of the company’s library of over three trillion synthesisable compounds.
Atomwise CEO and co-founder Abraham Heifets said: “At Atomwise , our mission is to use our unique technology to make better medicines faster by unlocking targets that have been inaccessible to traditional small molecule discovery approaches.
“We are pleased to enter into this collaboration with Sanofi , which serves as continued validation of the important role that AI-powered platforms will play in accelerating the discovery of new therapies for diseases and conditions that may have gone untreated due to challenging or uncharacterised drug targets.”
Under the multi-target collaboration, Atomwise will receive an upfront payment of $20m from Sanofi for identifying, synthesising and progressing lead compounds for up to five targets.
These targets will be exclusive to Sanofi .
Atomwise is also eligible to receive additional research, development and sales-based milestone payments totalling to over $1bn.
Furthermore, Sanofi will make tiered royalty payments on products that are developed under this partnership.
Sanofi Research global head and chief scientific officer Frank Nestle said: “At Sanofi , we are committed to bringing higher quality medicines to patients faster, empowered by our advanced AI drug discovery engine.
“Together, we aim at making the drug discovery process more efficient and effective, in particular when very limited information is available to support drug design.”
In March, Sanofi signed an exclusive global partnership agreement with IGM Biosciences to develop immunoglobulin M antibody agonists for oncology, immunology and inflammation targets.
Source: pharmaceutical-technology.com
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
